Antiatherosclerotic effects of calcium channel blockers

Progress in Cardiovascular Diseases

Volumn 45, Issue 1, 2002, Pages 1-20

  Mancini, G B John ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANIPAMIL; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIURETIC AGENT; GALLOPAMIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LIPID; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PRAVASTATIN; RONIPAMIL; VERAPAMIL;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; B SCAN; BLOOD VESSEL TONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CLASSIFICATION; DRUG EFFECT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LEUKOCYTE; LIPID METABOLISM; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; OUTCOMES RESEARCH; PERMEABILITY; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036322935     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.122694     Document Type: Article

References (91)

1. Calcium channel blockers and atherosclerosis
2. The role of calcium antagonists in the treatment of atherosclerosis and hypertension
3. A review of calcium antagonists and atherosclerosis
4. Antiatherogenic properties of calcium antagonists
5. A new generation of calcium antagonists and the role in atherosclerosis
6. 2+ antagonist lanthanum
7. Calcium antagonists and atherosclerosis
8. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine
9. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits
10. Verapamil suppresses atherosclerosis in cholesterol-fed rabbits
11. Mechanisms of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit
12. Verapamil and diet halt progression of atherosclerosis in cholesterol-fed rabbits
13. Vascular calcium overload - A pathogenic factor in arteriosclerosis and its neutralization by calcium antagonists
14. Antiatherogenic effects of calcium-channel blockers: Possible mechanisms of action
15. Calcium antagonists in comparison: View of the pharmacologist
16. Classification and tissue selectivity of calcium antagonists
17. 2+ channel blockers
18. The role of calcium in the pathogenesis of experimental arteriosclerosis
19. Antiperoxidative effects of calcium antagonists and atherogenesis
20. Actions of the charged dihydropyridine amlodipine in a cell culture model of dietary atherosclerosis
21. Cholesterol, calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection?
22. Differential membrane interactions of calcium channel blockers: Implications for antioxidant activity
23. Endothelial function: General considerations
24. Examination of monocyte adherence to endothelium under hyperglycaemic conditions
25. An atherogenic diet rapidly induces VCAM-1, a cytokine-reglulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium
26. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear monocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
27. LDL induces surface expression of adhesion molecules ICAM- 1 and VCAM on endothelial cells via the activation of protein kinase C
28. Effect of activation on adhesion of flowing neutrophils to cultured endothelium: Time course and inhibition by a calcium channel blocker (nitrendipine)
29. Stimulated leukocyte adhesion in coronary microcirculation is reduced by a calcium antagonist
30. Effect of felodipine-ER on blood pressure, platelet function, and rheological properties in hypertension
31. Influence of a single dose of nitrendipine on whole blood platelet activity in healthy subjects
32. Changes in sensitivity to angiotensin II in platelets
33. Verapamil impairs human neutrophil chemotaxis by a non-calcium-mediated mechanism
34. Nisoldipine inhibits formyl-methionyl-leucyl-phenylalanine (fMet-Leu-Phe) receptor-coupled transport in human neutrophils
35. 2-production in human alveolar macrophages
36. Inhibition of macrophage function by calcium channel blockers and calmodulin antagonists
37. Endothelin activates the dihydropyridine-sensitive, voltage-dependent calcium channel in vascular smooth muscle
38. Regulation of differentiated properties of arterial smooth muscle cells
39. Atherosclerosis, cell motility, calcium, and calcium-channel blockers
40. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation
41. Calcium antagonists and vascular smooth muscle cells in atherogenesis
42. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum
43. Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: Role of protein kinase C
44. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture
45. Regression of atherosclerosis: A role for calcium antagonists
46. Effects of the calcium channel antagonist verapamil on in vitro synthesis of skeletal collagen and non-collagen proteins
47. Antiatherosclerotic properties of calcium antagonists
48. Antiatherosclerotic effects of verapanil in primary culture of human aortic intimal cells
49. Effects of calcium antagonists on lipids and atherosclerosis
50. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries
51. Hypoxia-induced von Willebrand factor release is blocked by verapamil
52. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent
53. Kinin-mediated coronary citric oxide production contributes to the therapeutic action of antiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment of heart failure
54. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts
55. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels
56. Endothelial receptor mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
57. Hormonal requirements for growth of arterial smooth muscle cells in vitro: An endocrine approach to atherosclerosis
58. Effect of nicardipine and verapamil on in vitro albumin transport in rabbit thoracic aorta
59. Densitometric measurement of increased endothelial permeability in arteriosclerotic plaques and inhibition od permeability under the influence of two calcium antagonists
60. 2+ antagonists and vascular disease
61. The effect of nifedipine on lipid and monocyte infiltration of the subendothelial space
62. Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells
63. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue
64. Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: An effect dissociable from calcium entry blockade
65. Verapamil enhances receptor-mediated endocytosis of low density lipoproteins by aortic cells in culture
66. Effects of verapamil on cholesteryl ester hydrolysis and reesterification in macrophages
67. Calcium antagonists and low density lipoprotein receptors
68. R. Ca++ antagonists and ACAT inhibitors promote cholesterol efllux from macrophages by different mechanisms
69. Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals
70. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives
71. Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension
72. Insulin sensitivity, glucose effectiveness, and betacell function in obese males with essential hypertension: Investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril)
73. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: Results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy)
74. A controlled trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis
75. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris
76. Can the progression of coronary sclerosis be influenced by calcium antagonists?
77. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients
78. Calcium channel blockers and atherosclerosis: Lessons from the Stanford Transplant Coronary Artery Disease/Diltiazem Trial
79. Calcium channel antagonists protect against the development of coronary artery disease following cardiac transplant
80. Two year follow-up of a prospective randomized study of dittiazem coadministration with cyclosporine after heart transplantation
81. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the coronary angioPlasty amlodipine REStenosis Study (CAPARES)
82. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events
83. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis
84. Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older patients
85. Our preoccupation with coronary luminology - The dissociation between clinical and angiographic findings in ischemic heart disease
86. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS)
87. Calcium channel blockers: Lessons learned from MIDAS and other clinical trials
88. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapmil or chlorthalidone on carotid intima-media thickness
89. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes
90. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels
91. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in sympomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)